Keren He is an associate in O'Melveny’s Beijing office. She focuses on capital Markets, corporate financing, PE/VC investment, and general corporate matters. Prior to joining O’Melveny, Karen worked as an associate at a major international law firm in Beijing, where she focused on capital markets, M&A, and private equity transactions. She also previously worked as an associate at one of China’s largest domestic law firms.
Capital Markets
- TYK Medicines (2410.HK) in its approximately US$74 million IPO and listing on the Hong Kong Stock Exchange
- Sunho Biologics in Approximately US$60 Million IPO and listing on the Hong Kong Stock Exchange
- Folangsi Co., Ltd (2499.HK) in its HK$155 million (approximately US$20.15 million) IPO and listing on the Hong Kong Stock Exchange
- Beijing UBOX Online Technology Corp. (2429.HK) in its approximately US$30 million IPO and listing on the Hong Kong Stock Exchange, marking the first Hong Kong listing of a company in the unmanned retail industry
- Beauty Farm Medical and Health Industry Inc. in its approximately US$100 million IPO and listing on the Hong Kong Stock Exchange
- Cryofocus Medtech (Shanghai) Co., Ltd. in its approximately US$27 million IPO and listing on the Hong Kong Stock Exchange
- 3D Medicines Inc. in its US$52 million IPO and listing on the Hong Kong Stock Exchange
- Gaush Meditech Ltd. in its US$86 million IPO and listing on the Hong Kong Stock Exchange
- Beijing Capital Jiaye Property Services Co., Limited in its H share public offering on the Hong Kong Stock Exchange*
- Horizon Construction Development Limited in its IPO and listing on the Hong Kong Stock Exchange*
- Citigroup as main sponsor in the IPO of American Depositary Shares of Canaan Inc. (NASDAQ: CAN) on the Nasdaq Global Market*
- Merrill Lynch and Citigroup as main sponsors in the IPO of Ascentage Pharma Group International (6855.HK) on the Hong Kong Stock Exchange*
Private Equity and M&A
- Distinct Healthcare in its US$60 million Series E financing
- IDG Energy Investment Limited in the Series A preferred shares investment in Xiaoju Kuaizhi Inc.*
- China Internet Investment Fund in the Series E-1 investment in Kuaishou Technology*
- CMBC International Asset Management Limited in the Series B investment in Suning Sports Group Limited*
- CR-CP Life Science Advisor Limited and New Alliance Capital in the Series E investment in CF PharmTech*
- JD Fountain Technology (Hong Kong) Limited in its acquisition of minority equity interest in a Japanese company
- China Cinda (HK) Asset Management Co Limited, ARA Capital Group Limited and Forchn International Pte. Ltd. in the acquisition of 100% equity interest in six Singapore companies
- Nanjing Estun Automation Company in its equity acquisition of Carl Cloos Schweißtechnik GmbH*
- Guangdong Wencan Die Casting Co., Ltd. in its equity acquisition of Le Bélier S.A.*
- Hangzhou Ruizhen Therapeutics Co., Ltd. in the drug-device collaboration with Surefire Medical, Inc.*
* Experience at local firms prior to joining O’Melveny
Languages
- Mandarin Chinese
- English
Admissions
- New York
Education
- Emory University, J.D.
- China University of Political Sciences and Law, LL.B.
Professional Activities
Bar Exam
- Passed Chinese Bar Exam
Related Practices
Related Regions